Quick Takeaways
- Matthew K. Fust has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,487,198.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Matthew K. Fust
- Location
- Novato, CA
- Summary
- The estimated net worth of Matthew K. Fust is at least $2,487,198 dollars as of 30 Sep 2025. Matthew K. Fust is the Director of Crinetics Pharmaceuticals, Inc. and owns shares of Crinetics Pharmaceuticals, Inc. (CRNX) stock worth about $1.02M. Matthew K. Fust is the Director of Ultragenyx Pharmaceutical Inc. and owns shares of Ultragenyx Pharmaceutical Inc. (RARE) stock worth about $985.4K. Matthew K. Fust is the Director of Neumora Therapeutics, Inc. and owns shares of Neumora Therapeutics, Inc. (NMRA) stock worth about $342.4K. Matthew K. Fust is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $137.5K.
- Signature
- /s/ Tobin Schilke, as attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Matthew K. Fust and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Crinetics Pharmaceuticals, Inc. ($1,021,911).
- Past-year value change for that position: -$716,000.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Matthew K. Fust
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | Director | $1,021,911 | -$716,000 | -41% | 26 Sep 2025 |
| RARE | Ultragenyx Pharmaceutical Inc. | Director | $985,391 | 15 May 2025 | ||
| NMRA | Neumora Therapeutics, Inc. | Director | $342,395 | 28 May 2025 | ||
| ATRA | Atara Biotherapeutics, Inc. | Director | $137,501 | 10 Jun 2025 |
Insider Transactions Reported by Matthew K. Fust:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.